The University of Texas MD Anderson Cancer Center has been awarded a $718,858 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "DISCOVERY OF NONCANONICAL ANTIGENS IN TRIPLE-NEGATIVE BREAST CANCER FOR DEVELOPMENT OF NOVEL T CELL THERAPIES." This 3-year grant, awarded on February 15, 2025, will support the center's efforts to identify novel cancer antigens and develop new T cell-based immunotherapies for triple-negative breast cancer, an aggressive form of the disease. As a prominent cancer research institution, MD Anderson regularly receives federal grants and contracts from agencies like the National Institutes of Health, Department of Defense, and Department of Veterans Affairs to advance various areas of cancer research, including basic, translational, and clinical studies.
Generated 3/4/25, 2:29 AM